$NVO News

Novo Nordisk Falls 2% as Wegovy Opens a German Front

Wegovy’s German Debut Opens a New Front for Novo Nordisk (NVO)

Novo Nordisk (CPSE:NOVO B), What Is Behind The Fresh Attention?

Reported Earlier: 'Novo Nordisk launches Wegovy weight-loss pill in Germany' - Reuters

Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?

Novo Nordisk: Why The Price Remains Stubbornly Low (Rating Downgrade)

Novo Nordisk: Don't Ignore This Dirt-Cheap Buying Opportunity

The Market Is (Still) Underestimating Novo Nordisk

Novo Nordisk Announces U.S. Availability Of Awiqli, Its First Once-Weekly Basal Insulin For Adults With Type 2 Diabetes

Novo Nordisk Q2 Adj. EPS $0.96 Beats $0.81 Estimate, Sales $12.209B Beat $11.350B Estimate

Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks

Novo Nordisk Reports DKK 6.3B Non-Recurring, Non-Cash Impairment Charges In Q2 Related To Intangible Pipeline Assets

Novo Nordisk Expects Outlook FY Adjusted Revenue Growth -6 To 0%; Q2 Adj Sales Up 7% At CER; Adj Operating Profit Up 11% At CER; Raises 2026 Adj Sales, Operating Profit Outlook To 0% To -6% At Cer; Improved Outlook Is Driven By Increased Expectations For Glp-1 Product Sales

Novo Nordisk Says Anti-Inflammatory Drug Trial Fails to Cut Cardiovascular Risk in High Risk Patients

Novo Nordisk Announces Ziltivekimab Did Not Translate Into Major Adverse Cardiovascular Events Risk Reduction During Phase 3 Trial In Patients With Atherosclerotic Cardiovascular Disease

Novo Nordisk: Too Late For A Great Opportunity

Novo Nordisk: Mr. Market Is Pricing In Success, But It's Too Early To Bank On That

JYSKE BANK Downgrades Novo Nordisk A (NVO)

Novo Nordisk (CPSE:NOVO B) Stock Fair Value Edges Higher As Analysts Rework Growth Assumptions

Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal